Stocks Health care SCNI
NASDAQ · Health careScinai Immunotherapeutics Ltd. (SCNI)
Scinai Immunotherapeutics Ltd. reported revenue of $1.3M in fiscal 2025, up 99.2% from a year earlier. It posted a net loss of $8.3M. In fiscal 2025 capital spending exceeded operating cash flow by $6.1M. At December 31, 2025 it held $1.7M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on April 1, 2026.
What Scinai Immunotherapeutics Ltd. does
Scinai Immunotherapeutics Ltd. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker SCNI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.3M | -$8.3M | n/a | -$6.1M |
| 2024 | $658K | $4.8M | n/a | -$6.3M |
| 2023 | n/a | -$6.5M | $0.00 | -$10M |
| 2022 | n/a | -$5.8M | $0.01 | -$8.1M |
| 2021 | n/a | -$8.2M | -$0.02 | -$7.6M |
| 2020 | n/a | -$1.4M | n/a | -$24.5M |
Where SCNI ranks in Health care
Latest SEC filings
What Scinai Immunotherapeutics Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 24, 2026
- September 21, 2026
- September 8, 2026
- August 27, 2026Form POS AM filing POS AM
- August 26, 2026
- August 19, 2026
- July 9, 2026Passive stake changed SCHEDULE 13G/A
- July 1, 2026Passive stake changed SCHEDULE 13G/A
- June 17, 2026
- June 15, 2026
Insider trades
What the people running Scinai Immunotherapeutics Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 16, 2026 | Reichman AmirChief Executive Officer, Director | Received as pay | 400,000,000 | - |
| June 16, 2026 | Germain MarkDirector | Received as pay | 120,000,000 | - |
Who owns SCNI
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Stone Daniel E.13G, passive with 1 related filers | 9.9% | July 1, 2026 |
| Lck Jnk 1 LLC13G, passive | 6.33% | July 9, 2026 |
Largest institutional holders
Insiders
2 insiders reported holding 831,637,600 shares in total, about $1.29B at the last price.
| Holder | Shares |
|---|---|
| Reichman AmirChief Executive Officer, Director | 711,637,600 |
| Germain MarkDirector | 120,000,000 |
Questions about SCNI
What does Scinai Immunotherapeutics Ltd. do?
Scinai Immunotherapeutics Ltd. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker SCNI.
Is Scinai Immunotherapeutics Ltd. profitable?
No. In fiscal 2025 it reported a net loss of $8.3M on revenue of $1.3M.
How much revenue does Scinai Immunotherapeutics Ltd. make?
In fiscal 2025 Scinai Immunotherapeutics Ltd. reported revenue of $1.3M. That is 99.2% more than a year earlier.
When did Scinai Immunotherapeutics Ltd. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on April 1, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the iPO registration (foreign issuer) from September 24, 2026.
Similar companies
Compare SCNI with
Follow SCNI
Get an email when Scinai Immunotherapeutics Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Follow SCNI: get an email when it filesWhere the numbers come from
Financial figures are the values Scinai Immunotherapeutics Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.